Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma
- 15 February 1993
- Vol. 71 (4) , 1214-1218
- https://doi.org/10.1002/1097-0142(19930215)71:4<1214::aid-cncr2820710407>3.0.co;2-t
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinomaCancer, 1992
- A Phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinomaCancer, 1992
- Fluorouracil and recombinant interferon alfa‐2a in advanced gastrointestinal neoplasmsBritish Journal of Haematology, 1991
- Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma assessment of activity and toxicityCancer, 1990
- Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.Journal of Clinical Oncology, 1990
- Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.Journal of Clinical Oncology, 1989
- Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.Journal of Clinical Oncology, 1989
- Interferon effects upon fluorouracil metabolism by HL-60 cellsBiochemical and Biophysical Research Communications, 1989
- A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.Journal of Clinical Oncology, 1989
- Treatment of Advanced Colorectal CancerHematology/Oncology Clinics of North America, 1989